WO2025149667 - ANTIBODY DRUG CONJUGATES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/149667
Publication Date
17.07.2025
International Application No.
PCT/EP2025/050621
International Filing Date
12.01.2025
Title **
[English]
ANTIBODY DRUG CONJUGATES AND USES THEREOF
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT ET LEURS UTILISATIONS
Applicants **
PHEON THERAPEUTICS LTD
Inventors
JACKSON, Paul
ZAWEL, Leigh
PROCOPIOU, George
LI, Fu
HUANG, Chi-Ting
Priority Data
63/620,510
12.01.2024
US
63/620,515
12.01.2024
US
63/620,517
12.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 10886 | |
| EPO | Filing, Examination, Granting | 155857 | |
| Japan | Filing, Examination, Granting | 5005 | |
| South Korea | Filing, Examination, Granting | 9850 | |
| USA | Filing, Examination, Granting | 51140 |
Total:
232,738
Contact Us
Abstract[English]
The present disclosure provides antibody-drug conjugates (ADCs) that specifically bind a tumor associated TAA and compounds thereof useful for treating a disease or disorder such as cancer.[French]
La présente divulgation concerne des conjugués anticorps-médicament (ADC) qui se lient spécifiquement à un TAA associé à une tumeur et des composés de celui-ci utiles pour traiter une maladie ou une affection trouble telle que le cancer.